Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New compound discovered that rapidly kills liver cancer

14.03.2012
Scientists have identified a new compound that rapidly kills hepatocellular carcinoma (HCC) cells, the most common form of liver cancer and fifth most common cancer worldwide, while sparing healthy tissue.

The compound, Factor Qunolinone Inhibitor 1 (FQI1), works by inhibiting an oncogene originally discovered by a team of researchers led by Devanand Sarkar, M.B.B.S., Ph.D., Harrison Scholar at Virginia Commonwealth University (VCU) Massey Cancer Center, Blick Scholar and assistant professor in the Department of Human and Molecular Genetics and member of the VCU Institute of Molecular Medicine at the VCU School of Medicine.

Recently published in the journal Proceedings of the National Academy of Sciences, the study demonstrates that HCC cells have what is known as an "oncogene addiction" to the transcription factor Late SV40 Factor (LSF). Oncogene addiction is a term used when a cancer cell is found to be dependent on a single gene to survive. Using the compound Factor Quinolinone Inhibitor 1 (FQI1), the scientists prevented LSF from binding to HCC DNA during the transcription process, which is the first step in a series of actions that lead to cell division and duplication. This action caused rapid HCC cell death in laboratory experiments and a dramatic reduction in tumor growth in mouse models with no observable toxicity to normal liver cells.

"We may be on the verge of developing a new, effective drug for liver cancer," said Sarkar. "In the last 2 to 3 years, we demonstrated the role of LSF in liver cancer and have been screening over 110,000 compounds to identify the ones that inhibit LSF function. We identified FQI1 as one of a class of effective compounds, but we never anticipated it would work this well."

Sarkar discovered LSF's role in liver cancer in 2010 when he demonstrated significantly higher LSF levels in HCC patients in comparison to healthy individuals, and showed that inhibition of LSF reduced the progression of HCC in laboratory experiments. This finding led to the collaboration between VCU and Boston University that resulted in the discovery of FQI1.

Now that FQI1 has been identified, pharmacokinetic studies are being conducted to determine how the drug behaves in the human body. Once the scientists have determined how the drug is absorbed, distributed, metabolized and eliminated from the body, they will work with clinicians to translate their findings into phase I clinical trials in patients with liver cancer.

"We have proven this compound is effective and nontoxic in living animals," said Sarkar. "While we won't know how FQI1 reacts in humans until the first clinical trial, we are very excited by our findings and hope they lead to a new drug for a disease that is currently very difficult to treat."

The lead investigators on this study were Trevor J. Grant and Joshua Bishop, Ph.D., from Boston University. In addition to Grant and Bishop, Sarkar collaborated with Ayesha Siddiq, Ph.D., Rachel Gredler and Xue-Ning Shen, M.D., from VCU School of Medicine; Jennifer Sherman and Kevin Fitzgerald, Ph.D., from Alnylam Pharmaceuticals, Inc.; Sriharsa Pradhan, Ph.D., from New England Biolabs, Inc.; Laura A. Briggs, Ph.D., and William H. Andrews, Ph.D., from Sierra Sciences, LLC; and Lisa Christadore, Girish Barot, Ph.D., Hang Gyeong Chin, Sarah Woodson, John Kavouris, Tracy Meehan, Scott E. Schaus, Ph.D., and Ulla Hansen, Ph.D., from Boston University.

The full manuscript is available online at: http://www.pnas.org/content/early/2012/03/02/1121601109.full.pdf+html

News directors: Broadcast access to VCU Massey Cancer Center experts is available through VideoLink ReadyCam. ReadyCam transmits video and audio via fiber optics through a system that is routed to your newsroom. To schedule a live or taped interview, contact John Wallace, (804) 628-1550.

About VCU Massey Cancer Center: VCU Massey Cancer Center is one of only 66 National Cancer Institute-designated institutions in the country that leads and shapes America's cancer research efforts. Working with all kinds of cancers, the Center conducts basic, translational and clinical cancer research, provides state-of-the-art treatments and clinical trials, and promotes cancer prevention and education. Since 1974, Massey has served as an internationally recognized center of excellence. It has one of the largest offerings of clinical trials in Virginia and serves patients in Richmond and in four satellite locations. Its 1,000 researchers, clinicians and staff members are dedicated to improving the quality of human life by developing and delivering effective means to prevent, control and ultimately cure cancer. Visit Massey online at www.massey.vcu.edu or call 877-4-MASSEY for more information.

About VCU and the VCU Medical Center: Virginia Commonwealth University is a major, urban public research university with national and international rankings in sponsored research. Located on two downtown campuses in Richmond, VCU enrolls more than 31,000 students in 211 certificate and degree programs in the arts, sciences and humanities. Sixty-nine of the programs are unique in Virginia, many of them crossing the disciplines of VCU's 13 schools and one college. MCV Hospitals and the health sciences schools of Virginia Commonwealth University compose the VCU Medical Center, one of the nation's leading academic medical centers. For more, see www.vcu.edu.

John Wallace | EurekAlert!
Further information:
http://www.vcu.edu

More articles from Health and Medicine:

nachricht Foods of the future
15.08.2018 | Georg-August-Universität Göttingen

nachricht New antibody analysis accelerates rational vaccine design
09.08.2018 | Scripps Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Unraveling the nature of 'whistlers' from space in the lab

A new study sheds light on how ultralow frequency radio waves and plasmas interact

Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

Im Focus: The “TRiC” to folding actin

Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.

Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...

Im Focus: Lining up surprising behaviors of superconductor with one of the world's strongest magnets

Scientists have discovered that the electrical resistance of a copper-oxide compound depends on the magnetic field in a very unusual way -- a finding that could help direct the search for materials that can perfectly conduct electricity at room temperatur

What happens when really powerful magnets--capable of producing magnetic fields nearly two million times stronger than Earth's--are applied to materials that...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

2018 Work Research Conference

25.07.2018 | Event News

 
Latest News

Unraveling the nature of 'whistlers' from space in the lab

15.08.2018 | Physics and Astronomy

Diving robots find Antarctic winter seas exhale surprising amounts of carbon dioxide

15.08.2018 | Earth Sciences

Early opaque universe linked to galaxy scarcity

15.08.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>